HKSE - Delayed Quote • HKD Alphamab Oncology (9966.HK) Follow Compare 3.240 -0.010 (-0.31%) At close: January 28 at 12:08:04 PM GMT+8 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 9966.HK 1D 5D -2.70% 1M -10.50% 3M -19.00% 6M 49.31% YTD -9.75% 1Y -29.10% 5Y -76.18% All -75.08% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: 9966.HK View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations High Growth Tech Stocks To Watch In January 2025 Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved High Growth Tech Stocks To Watch In December 2024 Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024 High Growth Tech Stocks To Watch In November 2024 Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024 Exploring High Growth Tech Stocks In Hong Kong IND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China High Growth Tech Stocks To Watch In Hong Kong This September 2024 Related Tickers RXK3.HM SELLAS Life Sciences Group Inc 1.0080 -27.27% 1530.HK 3SBIO 6.010 -3.22% HALO Halozyme Therapeutics, Inc. 55.83 -0.30% SRNE Sorrento Therapeutics, Inc. 0.0005 -90.00% REGN Regeneron Pharmaceuticals, Inc. 687.27 +0.14%